Hall C B, Lee H, Alexson C, Meagher M P, Manning J A
J Infect Dis. 1977 Dec;136 Suppl:S648-51. doi: 10.1093/infdis/136.supplement_3.s648.
A vaccine trial involving 50 high-risk infants, aged six to 36 months, was performed for evaluation of the safety of a split-virus bivalent influenza A vaccine. After immunization, 18% of the infants developed a fever of greater than or equal to 100 F and 7% had fever of greater than or equal to 102 F. Other reactions to the vaccine were few. However, the reaction index of these high-risk infants to the bivalent vaccine was higher than those of older children receiving the same vaccine and normal infants receiving the monovalent vaccine. Forty-one percent of the infants responded with a titer of hemagglutination-inhibiting antibody of greater than or equal to 1:20 to the A/Victoria/75 component of the bivalent vaccine, and 35% responded to the A/New Jersey/8/76 component. This result suggested that this vaccine used in two doses would be an effective vaccine for infants. The infants generally tolerated the vaccine well. Nevertheless, the rapid development of fever would be of concern in the infant whose underlying disease was marginally compensated.
对50名6至36个月大的高危婴儿进行了一项疫苗试验，以评估一种裂解病毒双价甲型流感疫苗的安全性。免疫后，18%的婴儿出现了体温大于或等于100华氏度的发热，7%的婴儿体温大于或等于102华氏度。对该疫苗的其他反应较少。然而，这些高危婴儿对双价疫苗的反应指数高于接种相同疫苗的大龄儿童以及接种单价疫苗的正常婴儿。41%的婴儿对双价疫苗的A/维多利亚/75成分的血凝抑制抗体效价大于或等于1:20，35%的婴儿对A/新泽西/8/76成分有反应。这一结果表明，两剂使用的这种疫苗对婴儿将是一种有效的疫苗。婴儿总体上对疫苗耐受性良好。然而，对于潜在疾病仅得到勉强代偿的婴儿，发热的快速出现仍会令人担忧。
